Literature DB >> 33726721

Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation.

Tuo Deng1,2,3, Wenwen Zhang1,2,3, Yanling Zhang1,2,3, Mengqi Zhang1,2,3, Zhikun Huan1,2,3, Chunxiao Yu1,2,3,4, Xiujuan Zhang1,2,3,4, Yan Wang5, Jin Xu6,7,8,9.   

Abstract

BACKGROUND: As the incidence of secretory osteoporosis has increased, bone loss, osteoporosis and their relationships with thyroid-stimulating hormone (TSH) have received increased attention. In this study, the role of TSH in bone metabolism and its possible underlying mechanisms were investigated.
METHODS: We analyzed the serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and TSH and the bone mineral density (BMD) levels of 114 men with normal thyroid function. In addition, osteoblasts from rat calvarial samples were treated with different doses of TSH for different lengths of time. The related gene and protein expression levels were investigated.
RESULTS: A comparison of the BMD between the high-level and low-level serum TSH groups showed that the TSH serum concentration was positively correlated with BMD. TSH at concentrations of 10 mU/mL and 100 mU/mL significantly increased the mRNA levels of ALP, COI1 and Runx2 compared with those of the control (P < 0.05, P < 0.01). Bone morphogenetic protein (BMP)2 activity was enhanced with both increased TSH concentration and increased time. The protein levels of Runx2 and osterix were increased in a dose-dependent manner.
CONCLUSIONS: The circulating concentrations of TSH and BMD were positively correlated with normal thyroid function in males. TSH promoted osteoblast proliferation and differentiation in rat primary osteoblasts.

Entities:  

Keywords:  BMD; Osteoblast; Osteoporosis; TSH

Year:  2021        PMID: 33726721      PMCID: PMC7968288          DOI: 10.1186/s12902-021-00715-8

Source DB:  PubMed          Journal:  BMC Endocr Disord        ISSN: 1472-6823            Impact factor:   2.763


  48 in total

Review 1.  Molecular mechanisms in coupling of bone formation to resorption.

Authors:  T Martin; Jonathan H Gooi; Natalie A Sims
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

2.  TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.

Authors:  Mira Siderova; Kiril Hristozov; Aleksandra Tsukeva
Journal:  Arch Endocrinol Metab       Date:  2018 Mar-Apr       Impact factor: 2.309

3.  Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.

Authors:  Graziella Mendonça Monteiro de Barros; Miguel Madeira; Leonardo Vieira Neto; Francisco de Paula Paranhos Neto; Laura Maria Carvalho Mendonça; Inayá Corrêa Barbosa Lima; Rossana Corbo; Maria Lucia Fleiuss Farias
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

4.  β-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation.

Authors:  Alisa Boutin; Elena Eliseeva; Marvin C Gershengorn; Susanne Neumann
Journal:  FASEB J       Date:  2014-04-10       Impact factor: 5.191

5.  Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years.

Authors:  Avi Leader; Racheli Heffez Ayzenfeld; Michael Lishner; Efrat Cohen; David Segev; Doron Hermoni
Journal:  J Clin Endocrinol Metab       Date:  2014-06-02       Impact factor: 5.958

Review 6.  Role of Thyroid Hormones in Skeletal Development and Bone Maintenance.

Authors:  J H Duncan Bassett; Graham R Williams
Journal:  Endocr Rev       Date:  2016-02-10       Impact factor: 19.871

7.  THRA and DIO2 mutations are unlikely to be a common cause of increased bone mineral density in euthyroid post-menopausal women.

Authors:  Apostolos Gogakos; John G Logan; Julian A Waung; J H Duncan Bassett; Claus C Glüer; David M Reid; Dieter Felsenberg; Christian Roux; Richard Eastell; Graham R Williams
Journal:  Eur J Endocrinol       Date:  2014-03-13       Impact factor: 6.664

Review 8.  Expanding the Role of Thyroid-Stimulating Hormone in Skeletal Physiology.

Authors:  Ramkumarie Baliram; Rauf Latif; Mone Zaidi; Terry F Davies
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-03       Impact factor: 5.555

9.  Follicle-Stimulating Hormone Increases the Risk of Postmenopausal Osteoporosis by Stimulating Osteoclast Differentiation.

Authors:  Jie Wang; Wenwen Zhang; Chunxiao Yu; Xu Zhang; Haiqing Zhang; Qingbo Guan; Jiajun Zhao; Jin Xu
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

Review 10.  Thyroid Hormone Diseases and Osteoporosis.

Authors:  Alessandro P Delitala; Angelo Scuteri; Carlo Doria
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

View more
  3 in total

1.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Jianyao Migu Granules in the Treatment of Osteopenic Low Back Pain.

Authors:  Zihao Qin; Ke Xu; Wen Mo; Jie Ye; Jinhai Xu
Journal:  J Pain Res       Date:  2022-09-01       Impact factor: 2.832

2.  Effects of Triterpene Soyasapogenol B from Arachis hypogaea (Peanut) on Differentiation, Mineralization, Autophagy, and Necroptosis in Pre-Osteoblasts.

Authors:  Hyung-Mun Yun; Joon Yeop Lee; Soo Hyun Kim; Il Keun Kwon; Kyung-Ran Park
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

3.  Thyroid Hormones Are Not Associated with Plasma Osteocalcin Levels in Adult Population with Normal Thyroid Function.

Authors:  Nikolina Pleić; Dubravka Brdar; Ivana Gunjača; Mirjana Babić Leko; Vesela Torlak; Ante Punda; Ozren Polašek; Caroline Hayward; Tatijana Zemunik
Journal:  Metabolites       Date:  2022-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.